Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health
Viatris, Inc. (NASDAQ:VTRS) reported strong Q2 2025 results, generating approximately $79 million in revenue from new products while reaffirming its full-year financial guidance.